Walker confirmed that trial activities will resume as soon as possible. Novavax’s upcoming Phase III trial will evaluate the ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Phase III trial results of the R21/Matrix-M vaccine developed by Oxford University and Serum Institute of India Pvt Ltd, leveraging Novavax's Matrix-M adjuvant, has confirmed high efficacy and ...

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

and allows companies to make and distribute a product during a public health emergency while the FDA continues to review a ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

NOVAVAX is recommended for adults 18 years ... the data gathered thus far was ”robust and met the EU criteria for efficacy, safety and quality.” When the vaccine studies were carried out ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today ...

The recent Phase I data for ORX750, aimed at sleep disorders, showed significant efficacy with a placebo-adjusted improvement ... focusing on stocks such as Cytokinetics, Novavax, and Trevi ...

The Novavax vaccine is the only non-mRNA updated COVID vaccine that has been available in the U.S. The vaccine had a 90% efficacy in its clinical trial, performing almost as well as the mRNA ...